Inventor · disambiguated record
E. Douglas Kramer
Also filed as: KRAMER E DOUGLAS
5 granted patents·4 pending applications·11 citations·filing 2016–2022
73Inventor score
Files withATHENEX HK INNOVATIVE LTD4ATHENEX INC2ATHENEX THERAPEUTICS LTD1ATNX SPV LLC1KINEX THERAPEUTICS HK LTD1
Top patents by PatentIndex Score
9 records- 0190US10617693B2Methods of treating and/or preventing actinic keratosisATHENEX INC·Filed 2018·Granted Apr 14, 2020·6 cites·25 claims
- 0287US11497750B2Methods of treating and/or preventing actinic keratosisATHENEX INC·Filed 2020·Granted Nov 15, 2022·2 cites·23 claims
- 0385US10849893B2Therapeutic combinations of orally administered docetaxel and a P-gp inhibitor for the treatment of cancerATHENEX HK INNOVATIVE LTD·Filed 2019·Granted Dec 1, 2020·2 cites·32 claims
- 0482US11389442B2Therapeutic combinations of orally administered docetaxel and a P-gp inhibitor for the treatment of cancerATHENEX HK INNOVATIVE LTD·Filed 2020·Granted Jul 19, 2022·1 cites·19 claims
- 0570US2023046869A1Therapeutic combinations of orally administered docetaxel and a p-gp inhibitor for the treatment of cancerATHENEX HK INNOVATIVE LTD·Filed 2022·Application pending·0 cites
- 0665US2023172942A1Methods of treating and/or preventing actinic keratosisATNX SPV LLC·Filed 2022·Application pending·0 cites
- 0764US2023172926A1THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF CANCERATHENEX THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 0856US11752139B2Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancerATHENEX HK INNOVATIVE LTD·Filed 2019·Granted Sep 12, 2023·0 cites·16 claims
- 0939US2018207148A1THERAPEUTIC COMBINATIONS OF ORALLY ADMINISTERED PACLITAXEL AND A P-gp INHIBITOR FOR THE TREATMENT OF CANCERKINEX THERAPEUTICS HK LTD·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when E. Douglas Kramer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →